Dimethylformamide dimethyl acetal → HCID 68313024, Verbindung
Reaktionsgleichung
[CH:1]([N:4]1[C:8]([C:9]2[N:10]=[C:11]3[C:17]4[CH:18]=[CH:19][C:20]([C:22](=[O:24])[CH3:23])=[CH:21][C:16]=4[O:15][CH2:14][CH2:13][N:12]3[CH:25]=2)=[N:7][C:6]([CH3:26])=[N:5]1)([CH3:3])[CH3:2].CO[CH:29](OC)[N:30]([CH3:32])[CH3:31]>>[CH3:29][N:30]([CH3:32])/[CH:31]=[CH:23]/[C:22]([C:20]1[CH:19]=[CH:18][C:17]2[C:11]3[N:12]([CH:25]=[C:9]([C:8]4[N:4]([CH:1]([CH3:3])[CH3:2])[N:5]=[C:6]([CH3:26])[N:7]=4)[N:10]=3)[CH2:13][CH2:14][O:15][C:16]=2[CH:21]=1)=[O:24]Komponenten
3
Versuchsvorschrift
1-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)ethanone (2.6 g, 0.0074 mol) and 1,1-Dimethoxy-N,N-dimethylmethanamine (0.98 mL, 0.0074 mol) was mixed in Xylenes (30 mL, 0.07 mol) and was heated to reflux and stirred overnight. LCMS showed complete conversion to desired product. The solvent was removed and (E)-3-(dimethylamino)-1-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)prop-2-en-1-one was used in the next step without further purification.
Aufarbeitung
- temperaturewas heated
- temperatureto reflux
Quellen und Nachweise
- ORD-Eintrag
- ord-724b190d7d8845f7a6d29f175d1af51e
- Quelldatensatz
- uspto-grants-2015_07
- Patentnummer
- US09090628B2
Notizen zur Reaktion
Wird geladen…